Currently it is extremely difficult to conduct clinical trials for Alzheimer's Disease (AD) treatments since it takes a long time to determine efficacy. An effective AD biomarker such as this blood test could provide much quicker feedback to tell whether and experimental drug is working or not. See for example: The Role of Biomarkers in Clinical Trials for Alzheimer Disease

A burned out CEO from a company that is in a death spiral (Pfizer) seems like a very unlikely choice. Let's hope that US is not following the same trajectory as Pfizer.

Opps, the above is reversed from what it should be. Inhibition of the RGS14 gene product would theoretically decrease visual memory while increasing hippocampal-based learning and memory.

Inhibiting the RGS14 gene product could be counter productive and in fact dangerous. While this strategy may enhance visual memory, it also may decrease hippocampal-based learning and memory: RGS14

Selecting universities: personal preference and rankings